Claude Bouchard

Bio: Claude Bouchard is an academic researcher from Pennington Biomedical Research Center. The author has contributed to research in topics: Body mass index & Obesity. The author has an hindex of 153, co-authored 1076 publications receiving 115307 citations. Previous affiliations of Claude Bouchard include Texas A&M University & University of Texas at Austin.

Association between serum high-density lipoprotein cholesterol and body composition in adult men

Abstract: The relationships between measurements of body composition and fasting serum high-density lipoprotein cholesterol (HDL-C) were assessed in 357 men aged 30 to 59 years. The sum of six skinfolds (triceps, biceps, subscapular, suprailiac, abdominal and medial calf), body density through underwater body weighing, lean body mass (kg), body-fat mass, and percent body fat, all three derived from the Siri equation, were obtained. Effects of age, sex, alcohol consumption, cigarette smoking, socioeconomic status, triglycerides, total cholesterol and current energy expenditure were statistically removed through multiple regression procedures. HDL-C was significantly associated with weight, weight/height, weight/height11, weight/height16, body density, body-fat mass, sum of six skinfolds, but not with height alone or lean body mass. These results suggest that, among the body composition measurements, the adipose component is the major contributor to the low but significant association between HDL-C and weight.

Na+-K+-ATPase α2-gene and skeletal muscle characteristics in response to long-term overfeeding

Abstract: The role of Na+-K+-ATPase α2-gene BglII polymorphism in the changes of skeletal muscle metabolic properties after a 100-day overfeeding protocol conducted with 12 pairs of monozygotic twins is repo...

Genetic variation at the adipsin locus and response to long-term overfeeding

Abstract: Objectives: The role of adipsin and adipsin Hinc II polymorphisms on the metabolic and body composition changes in response to overfeeding was studied. Subjects: A total of 12 pairs of male monozygotic twins ate a 4.2 MJ/day energy surplus, 6 days a week, during a period of 100 days. Results: The preoverfeeding plasma adipsin concentration correlated positively with the change in CT-measured abdominal total and subcutaneous (P<0.05) fat. The changes in abdominal total fat and abdominal subcutaneous fat correlated negatively with changes in plasma adipsin concentrations (P<0.005). Overfeeding induced greater increases in body weight, fat mass, abdominal total and subcutaneous fat (P<0.05) in 6.1 kb noncarriers (n=10) than in 6.1 kb carriers (n=14) of the adipsin Hinc II polymorphism. The 6.1 kb noncarriers had a greater increase in plasma leptin levels (P<0.01). Also the total (P<0.01) and very-low-density lipoprotein (VLDL)-triglycerides (P<0.05), apolipoprotein B (P<0.05) and VLDL-cholesterol (P<0.05) levels increased more in the 6.1 kb noncarriers than in the 6.1 kb carriers. Conclusions: Adipsin plasma level could be a predictor of the changes in abdominal subcutaneous fat during times of increased energy intake. However, a greater increase in the abdominal subcutaneous fat was related to a lower increase in the plasma adipsin level. The adipsin Hinc II 6.1 kb allele noncarriers gained more abdominal subcutaneous fat and had a greater increase in plasma levels of leptin- and triglyceride-rich lipoproteins when exposed to a long-term positive energy balance. These findings provide new information on the role of adipsin on individual differences in response to chronically elevated food intake.

Red blood cell genetic variation in Olympic endurance athletes

Abstract: In an attempt to associate genetic variation with endurance performance, red cell antigens ABO, MNSs, Rhesus, Duffy, Kell, P and red cell enzymes lactate dehydrogenase (EC: 11127), malate dehydrogenase (EC: 11137), phosphoglucomutasej (EC: 2751) and phosphogluconate dehydrogenase (EC: 11144) genetic systems were studied in 79 Caucasian athletes who participated in endurance sports during the 1976 Montreal Olympic Games Gene frequencies were reported and phenotype frequencies were compared to appropriate reference populations No significant differences were observed between the athletes and the nonathletic populations of reference Comparisons of three genetic systems could be made with a sample of athletes from the 1968 Mexico Olympic Games Phenotype frequencies were identical in the two samples of athletes The search for genetic variants associated with endurance performance should continue for other genetic systems, particularly in skeletal muscle and other tissues related even

Dose-Response Issues Concerning the Relations between Regular Physical Activity and Health.

Abstract: This paper categorizes the many benefits of physical activity, offering information concerning the type of dose necessary to get that benefit. In 2000, Health Canada and the United States Centers for Disease Control and Prevention, along with other agencies, sponsored a symposium to determine whether there was a dose-response relationship between physical activity and several health related outcomes. A group of 24 experts from six countries reviewed the published research on several health outcomes (all-cause mortality, cardiovascular disease, type 2 diabetes mellitus, cancer, blood pressure, body weight and body composition, bone density, blood lipids and lipoproteins, hemostatic factors, low back pain and osteoarthritis, and quality of life and independent living in the elderly, depression, and anxiety. Results showed ample evidence supporting the beneficial effects of regular physical activity on all reviewed health outcomes. There was a strong suggestion of an inverse and linear relationship between regular physical activity and rates of all-cause mortality, total cardiovascular disease, coronary heart disease incidence and mortality, and incidence of type 2 diabetes mellitus. For other health outcomes, the doseresponse relationship with physical activity was less clear. (Contains 15 references.) (SM) Reproductions supplied by EDRS are the best that can be made from the original document. Dose-Response Issues Concerning the Relations Between Regular Physical Activity and Health Tuomo Rankinen and Claude Bouchard

International physical activity questionnaire: 12-country reliability and validity

Abstract: CRAIG, C. L., A. L. MARSHALL, M. SJOSTROM, A. E. BAUMAN, M. L. BOOTH, B. E. AINSWORTH, M. PRATT, U. EKELUND, A. YNGVE, J. F. SALLIS, and P. OJA. International Physical Activity Questionnaire: 12-Country Reliability and Validity. Med. Sci. Sports Exerc., Vol. 35, No. 8, pp. 1381-1395, 2003. Background: Physical inactivity is a global concern, but diverse physical activity measures in use prevent international comparisons. The International Physical Activity Questionnaire (IPAQ) was developed as an instrument for cross-national monitoring of physical activity and inactivity. Methods: Between 1997 and 1998, an International Consensus Group developed four long and four short forms of the IPAQ instruments (administered by telephone interview or self-administration, with two alternate reference periods, either the "last 7 d" or a "usual week" of recalled physical activity). During 2000, 14 centers from 12 countries collected reliability and/or validity data on at least two of the eight IPAQ instruments. Test-retest repeatability was assessed within the same week. Concurrent (inter-method) validity was assessed at the same administration, and criterion IPAQ validity was assessed against the CSA (now MTI) accelerometer. Spearman's correlation coefficients are reported, based on the total reported physical activity. Results: Overall, the IPAQ questionnaires produced repeatable data (Spearman's clustered around 0.8), with comparable data from short and long forms. Criterion validity had a median of about 0.30, which was comparable to most other self-report validation studies. The "usual week" and "last 7 d" reference periods performed similarly, and the reliability of telephone administration was similar to the self-administered mode. Conclusions: The IPAQ instruments have acceptable measurement properties, at least as good as other established self-reports. Considering the diverse samples in this study, IPAQ has reasonable measurement properties for monitoring population levels of physical activity among 18- to 65-yr-old adults in diverse settings. The short IPAQ form "last 7 d recall" is recommended for national monitoring and the long form for research requiring more detailed assessment. Key Words: MEASUREMENT, SURVEILLANCE, EPIDEMIOLOGY

2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Abstract: ABCD : Appropriate Blood pressure Control in Diabetes ABI : ankle–brachial index ABPM : ambulatory blood pressure monitoring ACCESS : Acute Candesartan Cilexetil Therapy in Stroke Survival ACCOMPLISH : Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE : angiotensin-converting enzyme ACTIVE I : Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ADVANCE : Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation AHEAD : Action for HEAlth in Diabetes ALLHAT : Antihypertensive and Lipid-Lowering Treatment to Prevent Heart ATtack ALTITUDE : ALiskiren Trial In Type 2 Diabetes Using Cardio-renal Endpoints ANTIPAF : ANgioTensin II Antagonist In Paroxysmal Atrial Fibrillation APOLLO : A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People ARB : angiotensin receptor blocker ARIC : Atherosclerosis Risk In Communities ARR : aldosterone renin ratio ASCOT : Anglo-Scandinavian Cardiac Outcomes Trial ASCOT-LLA : Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm ASTRAL : Angioplasty and STenting for Renal Artery Lesions A-V : atrioventricular BB : beta-blocker BMI : body mass index BP : blood pressure BSA : body surface area CA : calcium antagonist CABG : coronary artery bypass graft CAPPP : CAPtopril Prevention Project CAPRAF : CAndesartan in the Prevention of Relapsing Atrial Fibrillation CHD : coronary heart disease CHHIPS : Controlling Hypertension and Hypertension Immediately Post-Stroke CKD : chronic kidney disease CKD-EPI : Chronic Kidney Disease—EPIdemiology collaboration CONVINCE : Controlled ONset Verapamil INvestigation of CV Endpoints CT : computed tomography CV : cardiovascular CVD : cardiovascular disease D : diuretic DASH : Dietary Approaches to Stop Hypertension DBP : diastolic blood pressure DCCT : Diabetes Control and Complications Study DIRECT : DIabetic REtinopathy Candesartan Trials DM : diabetes mellitus DPP-4 : dipeptidyl peptidase 4 EAS : European Atherosclerosis Society EASD : European Association for the Study of Diabetes ECG : electrocardiogram EF : ejection fraction eGFR : estimated glomerular filtration rate ELSA : European Lacidipine Study on Atherosclerosis ESC : European Society of Cardiology ESH : European Society of Hypertension ESRD : end-stage renal disease EXPLOR : Amlodipine–Valsartan Combination Decreases Central Systolic Blood Pressure more Effectively than the Amlodipine–Atenolol Combination FDA : U.S. Food and Drug Administration FEVER : Felodipine EVent Reduction study GISSI-AF : Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation HbA1c : glycated haemoglobin HBPM : home blood pressure monitoring HOPE : Heart Outcomes Prevention Evaluation HOT : Hypertension Optimal Treatment HRT : hormone replacement therapy HT : hypertension HYVET : HYpertension in the Very Elderly Trial IMT : intima-media thickness I-PRESERVE : Irbesartan in Heart Failure with Preserved Systolic Function INTERHEART : Effect of Potentially Modifiable Risk Factors associated with Myocardial Infarction in 52 Countries INVEST : INternational VErapamil SR/T Trandolapril ISH : Isolated systolic hypertension JNC : Joint National Committee JUPITER : Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin LAVi : left atrial volume index LIFE : Losartan Intervention For Endpoint Reduction in Hypertensives LV : left ventricle/left ventricular LVH : left ventricular hypertrophy LVM : left ventricular mass MDRD : Modification of Diet in Renal Disease MRFIT : Multiple Risk Factor Intervention Trial MRI : magnetic resonance imaging NORDIL : The Nordic Diltiazem Intervention study OC : oral contraceptive OD : organ damage ONTARGET : ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial PAD : peripheral artery disease PATHS : Prevention And Treatment of Hypertension Study PCI : percutaneous coronary intervention PPAR : peroxisome proliferator-activated receptor PREVEND : Prevention of REnal and Vascular ENdstage Disease PROFESS : Prevention Regimen for Effectively Avoiding Secondary Strokes PROGRESS : Perindopril Protection Against Recurrent Stroke Study PWV : pulse wave velocity QALY : Quality adjusted life years RAA : renin-angiotensin-aldosterone RAS : renin-angiotensin system RCT : randomized controlled trials RF : risk factor ROADMAP : Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention SBP : systolic blood pressure SCAST : Angiotensin-Receptor Blocker Candesartan for Treatment of Acute STroke SCOPE : Study on COgnition and Prognosis in the Elderly SCORE : Systematic COronary Risk Evaluation SHEP : Systolic Hypertension in the Elderly Program STOP : Swedish Trials in Old Patients with Hypertension STOP-2 : The second Swedish Trial in Old Patients with Hypertension SYSTCHINA : SYSTolic Hypertension in the Elderly: Chinese trial SYSTEUR : SYSTolic Hypertension in Europe TIA : transient ischaemic attack TOHP : Trials Of Hypertension Prevention TRANSCEND : Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease UKPDS : United Kingdom Prospective Diabetes Study VADT : Veterans' Affairs Diabetes Trial VALUE : Valsartan Antihypertensive Long-term Use Evaluation WHO : World Health Organization ### 1.1 Principles The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology …

Standards of Medical Care in Diabetes

Abstract: XI. STRATEGIES FOR IMPROVING DIABETES CARE D iabetes is a chronic illness that requires continuing medical care and patient self-management education to prevent acute complications and to reduce the risk of long-term complications. Diabetes care is complex and requires that many issues, beyond glycemic control, be addressed. A large body of evidence exists that supports a range of interventions to improve diabetes outcomes. These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care. While individual preferences, comorbidities, and other patient factors may require modification of goals, targets that are desirable for most patients with diabetes are provided. These standards are not intended to preclude more extensive evaluation and management of the patient by other specialists as needed. For more detailed information, refer to Bode (Ed.): Medical Management of Type 1 Diabetes (1), Burant (Ed): Medical Management of Type 2 Diabetes (2), and Klingensmith (Ed): Intensive Diabetes Management (3). The recommendations included are diagnostic and therapeutic actions that are known or believed to favorably affect health outcomes of patients with diabetes. A grading system (Table 1), developed by the American Diabetes Association (ADA) and modeled after existing methods, was utilized to clarify and codify the evidence that forms the basis for the recommendations. The level of evidence that supports each recommendation is listed after each recommendation using the letters A, B, C, or E.